Literature DB >> 28001486

B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.

Peter A Calabresi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28001486     DOI： 10.1056/NEJMe1614717

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Can ad hoc analyses of clinical trials help personalize treatment decisions?

Authors:  Eman Biltaji; Shaun S Kumar; Elena Y Enioutina; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

2.  Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.

Authors:  Rita Kansal; Noah Richardson; Indira Neeli; Saleem Khawaja; Damian Chamberlain; Marium Ghani; Qurat-Ul-Ain Ghani; Louisa Balazs; Sarka Beranova-Giorgianni; Francesco Giorgianni; James N Kochenderfer; Tony Marion; Lorraine M Albritton; Marko Radic
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

3.  The Future of Immunotherapy: A 20-Year Perspective.

Authors:  David C Wraith
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

Review 4.  NLR-Dependent Regulation of Inflammation in Multiple Sclerosis.

Authors:  Marjan Gharagozloo; Katsiaryna V Gris; Tara Mahvelati; Abdelaziz Amrani; John R Lukens; Denis Gris
Journal:  Front Immunol       Date:  2018-01-18       Impact factor: 7.561

Review 5.  The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities.

Authors:  Grant P Parnell; David R Booth
Journal:  Front Immunol       Date:  2017-04-18       Impact factor: 7.561

Review 6.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

7.  CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.

Authors:  Mario Bunse; Janina Pfeilschifter; Julia Bluhm; Maria Zschummel; Jara J Joedicke; Anthea Wirges; Helen Stark; Vivien Kretschmer; Markus Chmielewski; Wolfgang Uckert; Hinrich Abken; Jörg Westermann; Armin Rehm; Uta E Höpken
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

8.  Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study.

Authors:  Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland; Lars Bø; Jan H Aarseth; Øivind Torkildsen
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-01-31

9.  Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis.

Authors:  Zhao-Lan Hu; Cong Luo; Plinio Reinaldo Hurtado; Hui Li; Shuang Wang; Bo Hu; Jun-Mei Xu; Yang Liu; Shi-Qing Feng; Ernesto Hurtado-Perez; Kang Chen; Xin-Fu Zhou; Chang-Qi Li; Ru-Ping Dai
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 10.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.